Immunoreactivity of progesterone receptor isoform B, nuclear factor κB, and IκBα in adenomyosis

Fertility and Sterility

Volumn 92, Issue 3, 2009, Pages 886-889

  Nie, Jichan ^a   Lu, Yuan ^a   Liu, Xishi ^a   Guo, Sun Wei ^b  

^a Shanghai Corps Hospital   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROGESTERONE RECEPTOR B; PROTEIN P50; PROTEIN P52; SYNAPTOTAGMIN I; VALPROIC ACID;

ADENOMYOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSMENORRHEA; ENDOMETRIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; CASE-CONTROL STUDIES; CELL NUCLEUS; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; I-KAPPA B PROTEINS; MENSTRUATION DISTURBANCES; MIDDLE AGED; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; RECEPTORS, PROGESTERONE; SEVERITY OF ILLNESS INDEX; TRANSCRIPTION FACTOR RELA;

EID: 69249212390     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.01.084     Document Type: Article

References (37)

1. Bergeron C., Amant F., and Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 20 (2006) 511-521
2. Farquhar C., and Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol 20 (2006) 603-616
3. Vercellini P., Vigano P., Somigliana E., Daguati R., Abbiati A., and Fedele L. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol 20 (2006) 465-477
4. Ota H., Igarashi S., Hatazawa J., and Tanaka T. Is adenomyosis an immune disease?. Hum Reprod Update 4 (1998) 360-367
5. Maia Jr. H., Maltez A., Studart E., Athayde C., and Coutinho E.M. Effect of menstrual cycle and hormonal treatment on ki-67 and bcl-2 expression and adenomyosis. Gynecol Endocrinol 20 (2005) 127-131
6. Ota H., Igarashi S., Sasaki M., and Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16 (2001) 561-566
7. Ota H., Igarashi S., and Tanaka T. Morphometric evaluation of stromal vascularization in the endometrium in adenomyosis. Hum Reprod 13 (1998) 715-719
8. Wu M.Y., and Ho H.N. The role of cytokines in endometriosis. Am J Reprod Immunol 49 (2003) 285-296
9. Kunz G., Beil D., Huppert P., Noe M., Kissler S., and Leyendecker G. Adenomyosis in endometriosis-prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 20 (2005) 2309-2316
10. Kunz G., Herbertz M., Beil D., Huppert P., and Leyendecker G. Adenomyosis as a disorder of the early and late human reproductive period. Reprod Biomed Online 15 (2007) 681-685
11. Bulun S.E., Cheng Y.H., Yin P., Imir G., Utsunomiya H., Attar E., Innes J., and Kim J. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol 248 (2006) 94-103
12. Guo S.W. Nuclear factor-kappab (NF-kappaB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large?. Gynecol Obstet Invest 63 (2007) 71-97
13. Shen F., Wang Y., Lu Y., Yuan L., Liu X., and Guo S.W. Immunoreactivity of progesterone receptor isoform B and nuclear factor kappa-B as biomarkers for recurrence of ovarian endometriomas. Am J Obstet Gynecol 199 (2008) 486 e1-486.e10
14. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), Wiley, New York
15. Inhaka R., and Gentleman R.R. R: a language for data analysis and graphics. J Comput Graph Stat 5 (1996) 1923-1927
16. Gonzalez-Ramos R., Donnez J., Defrere S., Leclercq I., Squifflet J., Lousse J.C., and Van Langendonckt A. Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod 13 (2007) 503-509
17. Dai D., Litman E.S., Schonteich E., and Leslie K.K. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol 87 (2003) 123-131
18. Dai D., Wolf D.M., Litman E.S., White M.J., and Leslie K.K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62 (2002) 881-886
19. Donnez J., Nisolle M., Smoes P., Gillet N., Beguin S., and Casanas-Roux F. Peritoneal endometriosis and "endometriotic" nodules of the rectovaginal septum are two different entities. Fertil Steril 66 (1996) 362-368
20. Matalliotakis I.M., Kourtis A.I., and Panidis D.K. Adenomyosis. Obstet Gynecol Clin North Am 30 (2003) 63-82
21. Hardy D.B., Janowski B.A., Corey D.R., and Mendelson C.R. Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-κB activation of cyclooxygenase 2 expression. Mol Endocrinol 20 (2006) 2724-2733
22. Cho S., Nam A., Kim H., Chay D., Park K., Cho D.J., Park Y., and Lee B. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 198 (2008) 373 e371-7
23. Yamamoto K., Arakawa T., Ueda N., and Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270 (1995) 31315-31320
24. Kunsch C., and Rosen C.A. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 13 (1993) 6137-6146
25. Cao S., Zhang X., Edwards J.P., and Mosser D.M. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 281 (2006) 26041-26050
26. Xing L., and Remick D.G. Promoter elements responsible for antioxidant regulation of MCP-1 gene expression. Antioxid Redox Signal 9 (2007) 1979-1989
27. Maxwell P.J., Gallagher R., Seaton A., Wilson C., Scullin P., Pettigrew J., et al. HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26 (2007) 7333-7345
28. Ulukus E.C., Ulukus M., Seval Y., Zheng W., and Arici A. Expression of interleukin-8 and monocyte chemotactic protein-1 in adenomyosis. Hum Reprod 20 (2005) 2958-2963
29. Ulukus M., Ulukus E.C., Seval Y., Cinar O., Zheng W., and Arici A. Expression of interleukin-8 receptors in patients with adenomyosis. Fertil Steril 85 (2006) 714-720
30. Wang F, Li H, Yang Z, Du X, Cui M, Wen Z. Expression of interleukin-10 in patients with adenomyosis. Fertil Steril. Published online April 24, 2008.
31. Nikkanen V., and Punnonen R. Clinical significance of adenomyosis. Ann Chir Gynaecol 69 (1980) 278-280
32. Kilkku P., Erkkola R., and Gronroos M. Non-specificity of symptoms related to adenomyosis. A prospective comparative survey. Acta Obstet Gynecol Scand 63 (1984) 229-231
33. Kumar A., Takada Y., Boriek A.M., and Aggarwal B.B. Nuclear factor-κB: its role in health and disease. J Mol Med 82 (2004) 434-448
34. Zhang N., and Oppenheim J.J. Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J Leukoc Biol 78 (2005) 1210-1214
35. Liu X., and Guo S.W. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril 89 (2008) 246-250
36. Matsuoka H., Fujimura T., Mori H., Aramori I., and Mutoh S. Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int Immunopharmacol 7 (2007) 1422-1432
37. Wu Y., and Guo S.W. Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 62 (2006) 193-205